Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282164 · ClinicalTrials.gov registry record · NA
The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis
A NA study of Adult Growth Hormone Deficiency and Hypothalamic-pituitary Disorders, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 4
- Study locations
NCT01282164: Completed NA study of Adult Growth Hormone Deficiency and Hypothalamic-pituitary Disorders, sponsored by The Cleveland Clinic.
NCT01282164 is a NA study of Adult Growth Hormone Deficiency and Hypothalamic-pituitary Disorders that has completed, run by The Cleveland Clinic. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01282164, a NA study of Adult Growth Hormone Deficiency and Hypothalamic-pituitary Disorders, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to find out if the Glucagon Stimulation Test (GST) is a reliable alternative to the Insulin Tolerance Test (ITT) for diagnosis of Growth Hormone Deficiency (GHD) and adrenal insufficiency. In some patients the accuracy of the GST for evaluation of adrenal insufficiency is compared to the adrenocorticotropin hormone (ACTH ) stimulation test.
Primary Outcome
The peak growth hormone (GH) during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease and 1-2 pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.
Conditions Studied
Interventions
- PROCEDURE Glucagon stimulation test and insulin tolerance test
- PROCEDURE glucagon stimulation test and insulin tolerance test
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- Cleveland Clinic Endocrinology, Diabetes and Metabolism - Cleveland
Oregon
- Oregon Health and Sciences University - Portland
Pennsylvania
- Allegheny Endocrinology Associates - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-07 |
| Phase | NA |
What the finished NCT01282164 record still lists
NCT01282164 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Adult Growth Hormone Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Glucagon stimulation test and insulin tolerance test is the first listed.
NCT01282164 reports a single indexed study location in Massachusetts, Ohio, Oregon.
Frequently Asked Questions
What is clinical trial NCT01282164 about?
NCT01282164 is a clinical study titled "The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis". The purpose of this study is to find out if the Glucagon Stimulation Test (GST) is a reliable alternative to the Insulin Tolerance Test (ITT) for diagnosis of Growth Hormone Deficiency (GHD) and adrenal insufficiency. In some patients the accuracy of the GST for evaluation of adrenal insufficiency i...
What is the current status of trial NCT01282164?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2011-01. Estimated completion is 2014-07.
What conditions does trial NCT01282164 study?
This clinical trial studies the following conditions: Adult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders.
What interventions are being tested in trial NCT01282164?
The interventions under investigation include: Glucagon stimulation test and insulin tolerance test (PROCEDURE), glucagon stimulation test and insulin tolerance test (PROCEDURE).
Who is sponsoring clinical trial NCT01282164?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01282164 being conducted?
This trial has 4 study locations across Massachusetts, Ohio, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Growth Hormone Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01282164's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia